Trichoscopy · Staging · CityLink Mall

Androgenetic Alopecia Singapore —
Shrinking, Not Falling

Pattern hair loss is not hair falling out faster than it should. It is hair growing back progressively thinner, shorter and paler with every cycle until it no longer reaches the surface — a process called miniaturisation, and one that behaves very differently from shedding.

The Mechanism

A Cycle That Shortens

Book a Consultation

Every follicle on the scalp runs a repeating cycle: a long growth phase called anagen, a brief transitional phase, and a resting phase that ends in the hair being released. Anagen determines how long a hair grows and therefore how thick and how long it becomes before it is shed. In androgenetic alopecia the anagen phase of susceptible follicles is progressively shortened, cycle after cycle, and the hair produced each time is a little finer and a little shorter than the one before it.

The signal driving that shortening is dihydrotestosterone. Testosterone is converted to DHT by the enzyme 5-alpha-reductase within the dermal papilla at the base of the follicle, and DHT binds androgen receptors there. In a follicle that carries the genetic susceptibility, that binding alters the growth signalling of the papilla. In a follicle that does not, exactly the same hormone concentration produces nothing at all — which is why the condition is patterned rather than uniform, and why men with identical testosterone levels can have entirely different scalps.

The visible consequence is miniaturisation. A terminal hair — thick, pigmented, long — is replaced across several cycles by an intermediate hair, then by a vellus hair, the fine colourless down that covers most of the body. The follicle is still there and still cycling. It is simply producing something that no longer provides coverage. This is why the scalp appears to thin before it appears to bald: the same number of follicles remain, but the total mass of hair each produces has collapsed.

Distribution follows androgen receptor density, not blood supply, hat-wearing or scalp tension. The frontal hairline, temples and vertex carry high receptor density; the occipital and lateral scalp carry very little. That regional difference is the entire basis of hair transplantation — follicles taken from the back of the head retain their resistance to DHT after they are moved, which is why a transplanted hairline persists while the native hair around it continues to recede.

Factor One
5-Alpha-Reductase
The enzyme that converts testosterone to DHT inside the dermal papilla. Its activity is higher in the frontal and vertex scalp than in the occipital scalp, which is one reason loss follows the pattern it does.
Factor Two
Receptor Susceptibility
Inherited, polygenic, and inherited from both sides of the family rather than the mother alone. Susceptibility determines whether a follicle responds to DHT at all — hormone levels themselves are usually entirely normal.
Factor Three
Anagen Shortening
Each cycle spends less time growing. The shaft produced is finer, shorter and less pigmented, and the proportion of follicles resting at any moment rises. Shedding increases as a secondary effect, not as the primary disease.
Factor Four
Non-Scarring
The follicular stem cell population in the bulge region survives. This is what makes the condition treatable — and what makes the window finite, because prolonged miniaturisation eventually ends in perifollicular fibrosis.

Classification

Four Diagnoses, One Mirror

The most consequential thing a consultation establishes is not how much hair has gone but which disease removed it. Miniaturisation, shedding, autoimmune attack and tension injury present to the same reader as thinner hair and respond to entirely different management. The distinction that matters most is whether the follicle is intact or has been replaced by scar.

Hair loss is a diagnosis before it is a treatment. Four conditions look identical in a mirror and only one of them responds to what most people buy for it.

Dr. Sin Yong · Medical Director, Atelier Aesthetics

Specifications

Type
Non-scarring, androgen-dependent, genetically determined
Assessment
Trichoscopy for shaft diameter variability, pull test, Norwood or Ludwig staging, bloods where indicated
Mechanism
DHT-driven progressive shortening of anagen and follicular miniaturisation
Review
Change assessed against standardised photography at 6 and 12 months, not weeks
Type I
Miniaturising
Androgenetic alopecia. Patterned, gradual, driven by DHT, and marked on trichoscopy by hairs of visibly different calibres sitting side by side. It progresses slowly and does not resolve on its own. Medical control through hair loss medications is the foundation of everything else.
Type II
Shedding
Telogen effluvium. Hair that was previously normal is released in synchrony after a trigger — illness, childbirth, surgery, rapid weight loss. It is usually self-limiting, and sudden shedding treated as pattern loss wastes months on the wrong problem.
Type III
Scarring
Cicatricial alopecia. Inflammation destroys the follicular unit and replaces it with fibrous tissue. There is no follicle left to stimulate, and no medication, laser or growth factor regrows hair from scar. Identifying it early is the only thing that changes the outcome, because treatment halts progression rather than reversing it.

Timing

What The Window Actually Is

Androgenetic alopecia is progressive by definition, and the practical consequence is that every treatment decision is really a decision about how much hair there is left to keep. A miniaturised follicle can be pushed back toward terminal calibre because the machinery is still present. A follicle that has been miniaturised for long enough undergoes perifollicular fibrosis, and at that point the ground is empty — the surface looks the same as it did the year before, but nothing will grow there again.

This is why the first question at consultation is density and calibre rather than symptom duration. Trichoscopy shows hair shaft diameter variability long before a mirror does, and standardised photography establishes the baseline against which anything is later judged. Without that baseline, a year of treatment produces an argument rather than an assessment, because hair changes too slowly for memory to be a reliable instrument.

Management is then built in layers rather than chosen from a menu. Medical therapy addresses the hormonal driver and is what stops the disease progressing; non-pharmacological follicle stimulation and regenerative approaches work on the follicles that remain; surgical redistribution moves DHT-resistant follicles into areas that have already been lost. The sequence matters — transplanting into a scalp whose native hair is still actively miniaturising produces a result that unravels around the graft within a few years.

The full hair restoration approach

FAQ

Androgenetic Alopecia — Common Questions

Ask a Question
Not exclusively, and the idea that you should look at your maternal grandfather is an oversimplification that has outlived its usefulness. Susceptibility is polygenic and contributed to by both parents. One well-characterised androgen receptor gene does sit on the X chromosome, which is where the story originates, but numerous autosomal loci are involved as well. A father with early recession is a meaningful signal, and so is a mother with a widening part.
Usually not. Most men and women with androgenetic alopecia have entirely normal androgen levels, and the variable is receptor sensitivity within the follicle rather than hormone concentration in the blood. This is why bodybuilders with suppressed natural testosterone can still lose hair, and why men with low-normal levels can be profoundly affected. In women, however, signs of genuine androgen excess — irregular cycles, acne, hirsutism — change the workup, because an underlying endocrine cause needs identifying before anything cosmetic is considered.
Yes, up to a point, and that point is the whole argument for treating early. A follicle that is still cycling and producing a fine hair retains its stem cell population and can be driven back toward terminal calibre. A follicle that has been miniaturised for years eventually undergoes fibrosis, and once the follicular unit has been replaced by scar tissue there is nothing left to stimulate. Nobody can tell you from a photograph which of your follicles are in which state — trichoscopy and response over six to twelve months answer it.
Because occipital follicles carry far lower androgen receptor density and lower 5-alpha-reductase activity than frontal and vertex follicles. They are constitutionally resistant to DHT, and they retain that resistance permanently — including after they have been surgically relocated. This is not a quirk of the condition; it is the mechanism that makes hair transplantation viable at all, and the reason a transplanted hairline behaves like the donor zone it came from rather than the recipient area it now occupies.
Six months at minimum for a meaningful signal and twelve for a fair judgement, because the hair cycle sets the pace and cannot be hurried. Anything assessed at eight weeks is measuring shedding, not growth. An increase in shedding during the first two to three months of some therapies is expected and is caused by resting follicles being pushed into a new growth phase — it is a poor reason to stop, and one of the more common causes of abandoned treatment.
Yes. Androgenetic alopecia is a chronic condition with an ongoing hormonal driver, and treatment suppresses that driver rather than removing it. Hair gained during treatment is maintained only while the treatment continues; discontinuation returns the scalp, over roughly a year, to where it would have been had nothing been done. That is an honest cost to weigh before starting, and it is a reason the plan should be one that can be sustained for years rather than one that is merely impressive for six months.

Continue

Related at Atelier

Atelier Aesthetics · Owned by AYA

Diagnosed properly —
then treated.

1 Raffles Link, #B1-28, CityLink Mall, Singapore 039393 · +65 8023 7170

Book a Consultation